Cue BioPharma
CUE----
Cue BioPharma (CUE)
Cue Biopharma, Inc., a clinical-stage therapeutics company, focuses on developing various therapies for immunological disorders. The company’s lead asset is CUE...
- Open
- --
- High
- --
- Low
- --
- Prev. Close
- --
- Volume
- --
- Turnover
- --
- Avg Price
- --
- Bid/Ask Ratio
- --
- Amplitude
- --
- 52wk High
- --
- Volume Ratio
- --
- Turnover Ratio
- --
Cue BioPharma Analyst Rating
View MoreForecast & Rating
May 15, 2026Price forecast
$115.00258.03%
Forecast & RatingStrong buy
1analysts
- Strong buy100.00%
- Buy0.00%
- Hold0.00%
- Sell0.00%
- Strong sell0.00%
News
- PUBT · Jul 15 at 05:58 PM
Cue Biopharma files Form 3 for Chief Medical Officer, Head of R&D Dominique Borie
- Price Alert · Jul 13 at 12:22 PM
U.S. stock market update: Cue Biopharma down 14.87%, executive appointments and financing raise concerns
- rttnews · Jul 13 at 07:55 AM
Cue Biopharma Appoints Dominic Borie As CMO
- rttnews · Jul 13 at 06:18 AM
Biotech Stocks At 52-Week Highs: AMWL, CUE, ICCC, SRRK, FTH
- TradingView · Jul 10 at 04:33 PM
Cue grants RSUs to CEO Shao-Lee Lin, CLO Sumita Ray and PAO Michael Meluzio
- TradingView · Jul 10 at 04:33 PM
Cue Biopharma Raises ~$50 Million in Private Placement With Cormorant, Columbia Threadneedle
